CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
C4 Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.89+0.13 (+4.52%)
Close on Oct 19, 2026
- Market cap
- $377.71M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.52 (+21.94%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
C4 Therapeutics, Inc. grew revenue 2.3% to $35.04M over the twelve months to Jun 30, 2026. Free cash flow was -$85.39M.
Revenue
$35.04M
+2.3% vs. a year earlier
Operating income
-$111.77M
TTM Q2 2026
Free cash flow
-$85.39M
TTM Q2 2026
EPS, diluted
-$0.99
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $377.71M
- P/E ratio
- –
- Price to sales
- 10.78
- Price to book
- 1.53
- Dividend yield
- –
- Free cash flow yield
- -22.61%
Fundamentals
- Revenue
- $35.04M
- Net income
- -$101.42M
- EPS, diluted
- -$0.99
- Free cash flow
- -$85.39M
- Book value per share
- $1.89
- Diluted shares
- 131M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$35.04M+2.3% YoY
Operating income
-$111.77M
Net income
-$101.42M
EPS, diluted
-$0.99
Free cash flow
-$85.39M
Reported periodTrailing twelve months